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Purpose: Previous studies have demonstrated that dopamine D1 and D4 receptor (D1R, D4R) 
agonists selectively improve spatial frequency and contrast sensitivity thresholds, respectively, in 
healthy and diabetic mice3,12. The purpose of this experiment was to investigate the selective 
benefits of three dopamine receptor agonists (D1R, D2R, D4R) on visual function, cognitive 
function, and blood glucose in a rat model of Type I diabetes with progression of diabetes.  
Methods: Streptozotocin (STZ) was used to induce hyperglycemia in 2-month-old male Long–
Evans rats (n=17). Outcome measures were acquired before and 30 minutes after an 
intraperitoneal injection of a single dose of a dopamine receptor agonist. Each agonist was 
injected 2-3 days apart. After 8, 16 and 20 weeks post-STZ, optomotor response (OMR) 
assessments were conducted. After 10 weeks post-STZ, blood glucose and Y-maze performance 
were measured on a subset of animals (n=4 diabetics; 6 controls). The spatial frequency, contrast 
sensitivity, Y-maze performance, and blood glucose for the diabetic rats and control rats post 
injection were compared to the baseline values to determine the effect of the acute dosing of each 
dopamine receptor agonist.  
Results: At the 8, 16, and 20 week timepoints, spatial frequency and contrast sensitivity 
thresholds were impaired in diabetic animals compared to controls (p<0.0001). At 8 weeks post-
STZ, D1R agonist selectively restored spatial frequency thresholds for diabetic rats (p<0.0001), 
but did not alter thresholds in control rats. At 8 weeks post-STZ, the D4R agonist selectively 
restored contrast sensitivity thresholds for diabetic rats (p<0.0001) but did not alter thresholds for 
control rats. The improvements that we observed at 8 weeks in the diabetic animals with the D1R 
and D4R agonists were no longer observed at 16 or 20 weeks. The D2R agonist did not 
demonstrate any effects at any timepoint. There was no significant differences in Y-maze and 
blood glucose values with agonist treatment.  
Conclusions: Based on these findings, acute dosing of dopamine receptor agonists selectively 
benefits visual acuity (D1R) and contrast sensitivity (D4R) at early stages of diabetic 
retinopathy. Thus, dopamine receptor agonists may provide protective treatment options for  





Diabetic retinopathy (DR) is a prominent cause of visual deficits and blindness in the United 
States and its incidence is predicted to rise15. Consequently, there is an important need for the 
development of early treatments to prevent progression of the disease. Dopamine has recently 
been identified as a neuroprotective agent for early stages of DR3. Furthermore, studies have 
demonstrated that the retinas of diabetic rodents show dopamine loss3. In our lab, we have 
demonstrated that treating rodents with L-DOPA, a precursor to dopamine that crosses the blood 
retinal barrier, provides protection against the visual impairments associated with DR3,14,18,19. 
The main objective of this study is to determine the efficacy of using dopamine receptor agonists 
to treat DR with progression of retinopathy. This study will fill important information gaps about 
which dopamine treatments are optimal for clinical use in diabetic retinopathy.  
 
Dopamine is prevalent in healthy retinal tissue, serving as a chemical messenger for light 
adaptation as well as playing a role in circadian rhythm function and vision21. Throughout the 
body, dopamine also stimulates vasodilation in tissue21. Since D2 receptors also modulate 
vascular epithelial growth factors, a decrease in dopamine levels has also been found to enhance 
the growth of certain tumors and lung cancer6. In combination, these findings lead us to believe 
that a loss of dopamine due to diabetes may potentially contribute to both the neural and vascular 
deficits seen in DR. In our lab, we have used optomotor response (OMR) and 
electroretinography (ERG) to demonstrate that treating rodents with L-DOPA during early stages 
of DR helps to prevent the loss in visual acuity and retinal function3,14,18,19.  
 
Dopamine is believed to travel through the retina via diffusion and binds to a variety of different 
cells that contain specific dopamine receptors21. Dopamine D1 receptors (D1R) are found in 
most retinal layers, dopamine D4 receptors (D4R) are found primarily in the photoreceptor 
layers, and dopamine D2 receptors (D2R) are found primarily on the dopaminergic amacrine 
cells and inner retinal neurons21. A dopamine receptor agonist is a chemical that binds to 
particular dopamine receptor types to initiate a response. Previous studies have demonstrated that 
treating diabetic mice with dopamine receptor agonists selectively restored visual impairments3. 
Specifically, the D1R agonist improved spatial frequency, while the D4R agonist improved 
contrast sensitivity3. These findings are promising because they suggest that even when 
dopamine levels are depleted, dopamine receptors remain intact. While the dopamine D2 
receptor agonist, bromocriptine, has been FDA approved for the treatment of diabetes, it has not 
yet been studied as a potential treatment for early DR.  
 
In this study, the effects of the dopamine receptor agonists D1R, D2R, and D4R on different 
aspects of visual function, cognitive function, and blood glucose levels will be examined. It is 
hypothesized that these dopamine receptor agonists will selectively restore visual deficits in a rat 
model of Type I diabetes after just one dose (acute effects). This experiment will help to 
elucidate whether dopamine receptor agonists effectively protect visual function in cases of DR, 
potentially offering therapeutic benefit without the potential side effects of L-DOPA. In addition, 




Significance of DR 
By the year 2025, 35% of the world’s population is expected to suffer from diabetes15. Due to 
this increase in the incidence in diabetes, the complications associated with diabetes are expected 
to burden healthcare systems throughout the world. In the United States alone, treatments for 
complications associated with diabetes are expected to cost approximately $336 billion per year 
by 203410. Diabetic retinopathy (DR), one of the more common complications associated with 
diabetes, is also the primary cause of blindness in working-age adults16. Further, on average, 
approximately 20 years after being diagnosed with diabetes, a majority of people develop DR16.  
 
Clinical Definition of DR 
Today, DR is clinically detectable by the presence of microaneurysms, dot hemorrhages or other 
microvascular lesions. When left untreated, the lack of blood flow to the retina results in 
neovascularization that ultimately leads to blindness7. At these late stages of the disease, known 
as proliferative DR, the only interventions that reduce the chance of blindness, such as pan-
retinal laser photocoagulation, vitreo-retinal surgery, or intravitreal injections of anti–vascular 
endothelial growth factor antibodies, are expensive and can result in some damage to retinal 
function9. Thus, there is a pressing need for a preventative treatment for this devastating disease.  
 
In order to develop an effective neuroprotective treatment for DR, researchers must first discover 
methods for diagnosing DR early, before detectable changes in retinal vascularization. 
Fortunately, studies have demonstrated that neuronal degeneration and deficits can be observed 
before this clinically observable vascularization1,4. Using electroretinograms (ERGs), a tool that 
enables the monitoring of retinal function, researchers have found that oscillatory potentials 
(OPs) are delayed or have altered amplitudes in both diabetic rodents and patients2,18,19. In 
addition to changes in ERGs, deficits in visual acuity, specifically night vision, contrast 
sensitivity, and color vision, have also been observed in diabetic patients before retinal 
neovascularization7. Preliminary studies using the optomotor response have found that diabetic 
rodent models also demonstrate visual deficits, specifically deficits in spatial frequency and 
contrast sensitivity, as early as 4 weeks post induction with diabetes2,3,14. In combination, these 
earlier studies have demonstrated that neuronal deficits can be detected before clinically 
detectible vascularization develops. 
 
Dopamine in Diabetes 
With this information, more recent studies have focused on introducing neuroprotective agents at 
the earliest observations of DR. Since the causes of the neuronal changes are not understood, 
scientists have experimented with different neuroprotective agents potentially lacking in the 
retinas of diabetic rodent models. In our lab, we have demonstrated that dopamine is reduced in 
the diabetic retina and increasing dopamine can protect against early neural dysfunction in 
diabetic rodent models3, suggesting that a deficiency of dopamine may be responsible for 
triggering the neuronal changes evident in early DR. 
 
It is reasonable to assume that there may be some dopamine deficiency in the retina since 
dopamine deficiency underlies several complications associated with diabetes. Cognitive 
deficits, depression, and Parkinson’s disease are all associated with dopamine deficiency in the 
brain that have been shown to occur more frequency in patients with diabetes11,17. Additionally, 
studies have shown that dopamine deficiency in the kidneys is associated with diabetic 
nephropathy, indicating that dopamine deficiency may be prevalent in multiple organ systems in 
diabetes22. Furthermore, the number of dopamine-releasing cells in the retina, also known as 
dopaminergic amacrine cells, has been shown to be decreased by 16% in later stages of diabetes 
in diabetic mouse models8. These findings have raised the question of whether both increasing 
levels of dopamine and/or activating dopamine receptors can prevent the neuronal and vascular 
deficits associated with DR. 
 
Dopamine Treatments for DR 
In further support of dopamine as an important factor in DR, we have found that dopamine 
deficiency results in early visual deficits with DR in diabetic rodents using optomotor response 
testing. In these studies, retinal tissue analysis showed that the type I diabetic rodent model 
possesses a deficiency in dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC), a dopamine 
metabolite that indicates the turnover of dopamine3. Furthermore, we have shown that increasing 
dopamine with L-DOPA treatment, the precursor for dopamine, results in protection against 
these deficits3,14. Retinal deficits were significantly reduced in diabetic rats treated with L-DOPA 
compared to the diabetic rats treated with vehicle. L-DOPA in the form of levodopa has been 
approved by the FDA for Parkinson’s patients since the 1960s. In a recent clinical trial in which 
the ERG results of individuals with diabetes given Sinemet treatments (levodopa plus carbidopa) 
were compared to the ERG results of controls, the treatment resulted in a reversal of retinal 
dysfunction, suggesting that the Sinemet treatment may be an exciting potential treatment option 
for early stage DR18.   
 
Unfortunately, L-DOPA may not be an ideal option for people who need chronic treatment since 
it has been associated with side effects such as motor deficits and dyskinesias in patients with 
Parkinson’s disease13. Since dopamine receptor agonists, like bromocriptine, are currently being 
clinically prescribed by doctors for diabetes and the side effects seem to be marginal, it is worth 
studying whether dopamine receptor agonists produced similar protective benefits to dopamine 
treatments. A dopamine receptor agonist is a substance that binds to a dopamine receptor type 
and activates the receptor to generate the biological response. The dopamine receptor agonists 
D1R and D4R have been shown to have selective effects on visual function in non-diabetic 
animals12.  It has also been demonstrated that acutely administering dopamine receptor agonists 
(D1R and D4R) to mice at 5 weeks post induction with diabetes selectively restored visual 
function3. Specifically, D1R agonists partially restored spatial frequency and D4 receptor 
agonists partially restored contrast sensitivity3. This suggests that the dopamine receptors are 
present and functioning in the retina even when dopamine levels are low and that acute dosing of 
dopamine receptor agonists may serve as a potential treatment option for functional deficits in 
the diabetic retina.   
 
Given this information, we aim to further assess whether dopamine receptor agonists may 
provide a protective effect against visual deficits characteristic of type I diabetes by testing the 
selective benefits of acute dosing with three dopamine receptor agonists (D1R, D2R, D4R) on 
visual function, cognitive function, and blood glucose in a rat model of type I diabetes at 
different stage of disease. In line with other studies, we expect to see that acute delivery of 





Animals and diabetes induction  
Twenty-nine male Long–Evans rats (Charles River Laboratories) were kept in ventilated cages 
with food and water and all procedures were approved by the Atlanta VA Institutional Animal 
Care and Use Committee. Ten rats (2-months old) were injected with a single dose of 
streptozotocin (STZ: 100 mg/kg; Sigma-Aldrich) dissolved in an eight to one ratio of citrate 
buffer and 50% glucose solution to induce hyperglycemia. Post-STZ, the blood glucose of these 
rats was monitored daily using a blood glucose meter and tail-prick blood. Rats were considered 
to be diabetic once blood glucose levels of greater than 250 mg/dL were observed two days in a 
row. This group served as the type 1 diabetic group (DM). For the duration of the experiment, 
the weight and blood glucose of these animals was monitored once a week. If a DM rat was 
observed to be losing significant weight, an insulin pellet (13  3 mg/pellet) was surgically 
placed subcutaneously (Linplant; Linshin, Canada) to avert future weight loss without 
diminishing the hyperglycemia. The rats were maintained for 12 to 20 weeks and then 
euthanized.  
Dopamine Receptor Agonist Acute Treatment 
Outcome measures (spatial frequency, contrast sensitivity, Y-maze, and blood glucose) were 
performed on diabetic rats (n=17) and control rats (n=12) before and 30 minutes after an 
intraperitoneal injection of a single dose of SKF38393 hydrobromide, a D1R agonist (1 mg/kg); 
bromocriptine mesylate, a D2R agonist (5 mg/kg); or PD168077 maleate, a D4R agonist (1 
mg/kg) (Tocris Biosciences). Since the half-lives of these drugs are between 1 and 3 hours, a 
two-day interval was allotted between treatments to completely ensure that there was no residual 
effects of the previous treatment3. Experimental design is shown in Figure 1.  
 
Figure 1: Diagram of experimental timeline. 
Analysis of visual function 
At 8, 16, and 20 weeks post-STZ, the virtual optomotor response system (OptoMotry system; 
Cerebral- Mechanics) was used to measure visual function, specifically contrast sensitivity and 
spatial frequency thresholds. The system consists of a box in which the four walls are monitors 
that present vertical lines moving from one side of the screen to the other. The rat was placed in a 
platform at the center of the 4 monitors and a camera was located above it, allowing for live 
observation of the animal’s visual tracking behavior. The rat was determined to be visually 
tracking the lines when its head was moving in the same direction and speed as the vertical lines.  
To assess for spatial frequency, the black vertical lines were maintained at 100% contrast and 
started moving at a spatial frequency of 0.042 cycles/degree. The spatial frequency increased 
until the rat could no longer visually track the lines. The spatial frequency threshold was the 
highest spatial frequency that the rat was observed visually tracking the lines three times using a 
staircase testing paradigm. To assess contrast sensitivity, the spatial frequency was held at 0.064 
cycles/degree and the contrast of the vertical lines decreased until the rat could no longer visually 
track the lines. The contrast sensitivity was then calculated for each animal by taking the 
luminance of the monitors displaying the vertical lines and calculating the reciprocal of the 
Michelson contrast [i.e., (maximum + minimum)/(maximum − minimum)], as described 
previously20.  
Analysis of cognitive and exploratory behavior – y-maze 
To determine spatial working memory and exploratory behavior, the y-maze (San Diego 
Instruments, San Diego, CA) was utilized. Rats were positioned in one arm of the y-maze and 
allowed to explore around the maze (8 min). The number of times the animal entered an arm was 
recorded. An alternation was defined as an animal entering the arms in a consecutive manner. 
The spatial alteration behavior (cognitive behavior) was calculated by taking the number of 
successful alternations and dividing it by the total number of entries minus two and multiplying 
by one hundred. Exploratory behavior was defined as the total number of arm entries during the 
8-minute time window.  
 
Analysis of blood glucose 
To determine the immediate effects of acute dosing with each dopamine receptor agonist on 
blood glucose levels, blood glucose was measured using a blood glucose meter that measured 
from tail-prick blood before and 30 minutes after the dopamine receptor agonist treatment.  
 
Statistical analysis  
Results are expressed as mean  standard error of the mean (SEM). Outcome measures were 
compared pre- and post-agonist between diabetic and control rats at 8, 10, 16, and 20 weeks 
post-STZ and then all agonists compared across time using three-way repeated ANOVAs 





Selective Effects of Acute Agonist Treatments on Visual Function 
We investigated how selective dopamine receptor agonists could reverse visual deficits in a rat 
model of type 1 diabetes by performing optomotor response evaluation on a group of 17 diabetic 
and 12 control rats before and after a single injection of a D1 receptor (D1R) agonist 
(SKF38393), a D2 receptor agonist (D2R) (5 mg/kg), or a D4 receptor (D4R) agonist 
(PD168077). At 8 weeks post-STZ, spatial frequency and contrast sensitivity thresholds were 
significantly worse in the diabetics than the control animals (Two-way ANOVA, main effect of 
diabetes, spatial frequency F(1, 27) = 139.6, p<0.0001; contrast sensitivity: F(1, 26) = 90.89, 
p<0.0001). In diabetic animals, D1R agonist treatment improved spatial frequency (Multiple 
comparison, p<0.0001), while D4R agonist improved contrast sensitivity (Multiple comparison,  
p<0.0001) (Figure 2). To measure the impacts of the agonist treatments during various stages of 
the disease, optomotor tracking evaluations were also performed at 16- and 20-week time points 
on a group of 4 diabetic and 6 control rats before and after each agonist treatment. By the 16- and 
20-week time points, the same selective benefits on visual function were not observed (Figure 
3).  
 
Figure 2: D1R agonist selectively increased spatial frequency while D4R agonist selectively increased contrast 
sensitivity at 8-week post-STZ. Baseline and post-agonist spatial frequency (left) and contrast sensitivity (right) 
thresholds for diabetics (n=17) and controls (n=12) at 8 weeks post-STZ demonstrate selective benefit with D1R and 





Figure 3: Benefits of dopamine agonists may decline with progression of diabetic retinopathy. Percent change 
in spatial frequency (left) and contrast sensitivity (right) thresholds at 8, 16, and 20 weeks post-STZ show that the 
selective benefits of D1R and D4R agonists decline with progression of the disease. Results expressed as mean ± 
SEM.  
 
Effects of Acute Agonist Treatments on Blood Glucose 
To assess whether the improvements in visual function due to agonist treatments involved 
changes in blood glucose, blood glucose analysis was performed on a group of 10 diabetic and 8 
control rats before and after an agonist injection. There were no significant differences 
demonstrated by blood glucose analyses (Figure 4). 
 
Figure 4: Blood glucose did not change with agonist treatment at 10-weeks post-STZ. 
Baseline and post agonist blood glucose values for diabetics (n=10) and controls (n=8) at 8 weeks post-STZ show 




D1R agonist D4R agonist 
Effects of Acute Agonist Treatments on Blood Glucose 
To assess whether agonist treatments impact cognitive function, a Y-maze was conducted on a 
group of 10 diabetic and 8 control rats before and after each agonist treatment. While diabetic 
rats displayed reduced spatial alternation and exploratory behavior relative to controls 
(p<0.0001), there was no significant differences between baseline and post-agonist values 
(Figure 5).  
 
  
Figure 5: Cognitive function measured with y-maze did not change with agonist treatment at 10-weeks post-
STZ. Baseline and post agonist spatial alternation (left) and exploratory behavior (right) for diabetics (n=10) and 
controls (n=8). Spatial alternation and exploratory behavior was reduced in diabetic animals; however, agonists do 
not effect spatial alternation and exploratory behavior. Results expressed as mean ± SEM. **p<0.001. 
 
Discussion 
Spatial Frequency and Contrast Sensitivity Thresholds Impaired in Type I Diabetic Rats  
The present study shows that early stages of DR impact certain aspects of visual function and 
therefore demonstrates that spatial frequency and contrast sensitivity may serve as useful 
diagnostic tools for early stages of DR. While some of these visual impairments may be due to 
the presence of cataracts, previous studies have demonstrated that as early as 4 weeks post-STZ, 
diabetic animals without cataracts display these visual deficits2. These findings suggest that other 
factors, such as the impact of hyperglycemia on retinal function, contributed to the development 
of visual deficits over time2. Future studies are necessary to identify the exact mechanism that 
connects these two pathologies.   
Dopamine Receptor Agonists Selectively Restore Visual Function in early stages of Type I 
Diabetic Rats 
In this study, in diabetic animals, D1R agonist treatment improved spatial frequency, while D4R 
agonist improved contrast sensitivity. No significant improvements were observed in controls. 
These results are consistent with the findings in a previous study that showed that acutely 
administering dopamine receptor agonists (D1R and D4R) to mice at 5 weeks post induction 
with diabetes selectively restored visual function3. These data suggest that the dopamine 
receptors are present and functioning in the retina even when dopamine levels are low, and that 
acute dosing of D1R and D4R agonists may serve as potential treatment options for patients with 
diabetes. Thus, the results of this current study support the idea that diabetes disturbs 
dopaminergic retinal pathways but keeps the dopaminergic receptors intact. The D2R agonist did 
not result in any significant improvements in diabetic or control animals. In future experiments, 
different concentrations of the D2R agonist used should be explored to determine whether the 
results observed were due to a suboptimal dosage of the drug. By the 16- and 20-week time 
points, the same selective benefits on visual function were not observed. This suggests that 
dopamine receptor agonists may only be useful as a treatment for DR in the early stages of the 
disease. However, it should be noted that since only 4 diabetics and 6 controls remained for these 
later time-points, future experiments will have to be conducted with more animals to determine 
whether or not the trends observed remain.  
Blood glucose did not change with acute dopamine receptor agonist treatment  
There were no significant differences demonstrated by blood glucose analyses, suggesting that 
the improvements in visual function observed at the 8-week timepoint were not due to a sudden 
change in blood glucose levels. Thus, this data supports the idea that dopamine agonist treatment 
is acting directly on the retina to restore dopamine and thus function is not acting through a 





Cognitive function measured with y-maze did not change with acute dopamine receptor 
agonist treatment  
While diabetic rats displayed reduced spatial alternation and exploratory behavior relative to 
controls, indicating impaired cognitive function, there were no significant differences between 
baseline and post-agonist values. This suggests that dopamine receptor agonists may not restore 
cognitive function in type I diabetic animals.  
 
Conclusions 
These results demonstrate that D1R agonists improve spatial frequency while D4R agonists 
improve contrast sensitivity at the early stages of diabetic retinopathy. This finding suggests that 
diabetes does not change the roles of D1R and D4R in vision, nor does it damage existing 
dopamine receptors in the retina. This research is clinically relevant because it shows that 
dopamine receptor agonists may be a helpful treatment in patients with early stages of diabetic 
retinopathy. This information will hopefully help fill important information gaps about which 
dopamine treatments are most optimal for clinical use in DR. Since the animal numbers for the 
later timepoints were smaller than the earlier timepoints, future studies may examine the role of 
dopamine receptor agonists on late stages of DR, during the appearance of vascular changes, a 
timepoint that is most clinically relevant to when diabetes is detected in the clinic. Since we did 
not observe any effects due to the D2 agonist, future studies with different dosages may be 
conducted to verify that the D2 agonist is not protective.  
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